Capmatinib

Kinase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Capmatinib is an onp drug in the Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2020. Its mechanism of action is classified as Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 1A2 Inhibitors and Mesenchymal Epithelial Transition Inhibitors. DrugCentral lists 2 molecular targets, including MET and CDKL5. Recorded indications include Metastatic non-small cell lung cancer.

• Approval status: onp (first approved 2020 by the FDA).
• Drug class: Kinase Inhibitor.
• Mechanism of action: Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 1A2 Inhibitors; Mesenchymal Epithelial Transition Inhibitors.
• Molecular targets: MET and CDKL5 (2 listed in DrugCentral).
• Indications: Metastatic non-small cell lung cancer.
• ATC code: L01EP01 (Cellular-mesenchymal-epithelial transition factor (c-MET) kinase inhibitors).
• Molecular formula: C23H17FN6O; molecular weight 412.43 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Metastatic non-small cell lung cancer

Mechanism & targets

• Mechanism of action (MoA): Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 1A2 Inhibitors; Mesenchymal Epithelial Transition Inhibitors; Multidrug and Toxin Extrusion Transporter 1 Inhibitors; Multidrug and Toxin Extrusion Transporter 2 K Inhibitors; P-Glycoprotein Inhibitors
• Established pharmacologic class: Kinase Inhibitor

Molecular targets (2)

Target	Gene	Action	Activity
Hepatocyte growth factor receptor	MET	inhibitor	IC50 9.88
Cyclin-dependent kinase-like 5	CDKL5	unknown	Kd 5.69

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2022-06-20	EMA	—	NOVARTIS EUROPHARM LIMITED
2020-06-29	PMDA	—	Novartis Pharma K.K.	Yes
2020-05-06	FDA	—	NOVARTIS PHARM	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01EP01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Cellular-mesenchymal-epithelial transition factor (c-MET) kinase inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: MET · Testing Required
• FDA label: MET · Testing Required
• HCSC label: MET · Testing Required

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Malignant neoplasm progression	465.9
Oedema peripheral	394.6
Death	234.3
Oedema	173.8
Non-small cell lung cancer	103.9
Dysphagia	101.4
Blood creatinine increased	89.2
Product use complaint	66.6
Generalised oedema	53.7
Deafness	48.5
Hepatic cytolysis	45.9
Disease progression	44.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Capmatinib is on its molecule page.

• Molecular formula: C₂₃H₁₇FN₆O
• Molecular weight: 412.43 g/mol
• CAS number: 1029712-80-8
• InChIKey: LIOLIMKSCNQPLV-UHFFFAOYSA-N
• PubChem CID: 25145656

CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Capmatinib used for?

DrugCentral lists the following indications for Capmatinib: Metastatic non-small cell lung cancer.

How does Capmatinib work?

Capmatinib is classified as Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 1A2 Inhibitors and Mesenchymal Epithelial Transition Inhibitors; its molecular targets in DrugCentral include MET (inhibitor) and CDKL5.

When was Capmatinib first approved?

Capmatinib was first approved by the FDA in 2020.

What drug class does Capmatinib belong to?

Capmatinib is in the Kinase Inhibitor class.

What is the chemical formula of Capmatinib?

Capmatinib has the molecular formula C23H17FN6O and a molecular weight of 412.43 g/mol.

Sources

• DrugCentral drug card 5392 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3188267 — compound record and bioactivity
• PubChem CID 25145656 — chemical identifiers
• DrugBank DB11791 — drug record
• FDA UNII TY34L4F9OZ — substance identity
• DailyMed: FDA labels for Capmatinib — current prescribing information (label search)
• UniProt P08581 (MET) — target protein
• UniProt O76039 (CDKL5) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.